{"id":"https://openalex.org/A5069334608","orcid":"https://orcid.org/0009-0007-8572-1729","observed_orcids":["https://orcid.org/0009-0007-8572-1729"],"display_name":"Naoshi Kunimura","raw_author_names":["Naoshi Kunimura"],"full_name":"Naoshi Kunimura","works_count":20,"cited_by_count":14,"summary_stats":{"2yr_mean_citedness":0.7,"h_index":2,"i10_index":0},"ids":{"openalex":"https://openalex.org/A5069334608","orcid":"https://orcid.org/0009-0007-8572-1729","observed_orcids":["https://orcid.org/0009-0007-8572-1729"]},"affiliations":[{"institution":{"id":"https://openalex.org/I4210147619","ror":"https://ror.org/042c70y92","display_name":"Fujimoto Pharmaceutical Corporation (Japan)","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210147619"]},"years":[2025,2024]}],"last_known_institutions":[{"id":"https://openalex.org/I4210147619","ror":"https://ror.org/042c70y92","display_name":"Fujimoto Pharmaceutical Corporation (Japan)","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210147619"]}],"topics":[{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","count":20,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","count":19,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","count":10,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11591","display_name":"NF-\u03baB Signaling Pathways","count":6,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","count":3,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"topic_share":[{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","value":0.0003359,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11591","display_name":"NF-\u03baB Signaling Pathways","value":7.07e-05,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","value":5.17e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","value":4.66e-05,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","value":1.17e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"x_concepts":[{"id":"185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","score":0.8842209577560425},{"id":"2779679103","wikidata":"https://www.wikidata.org/wiki/Q5251805","display_name":"Degradation (telecommunications)","score":0.6443378925323486},{"id":"2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","score":0.5747737884521484},{"id":"41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","score":0.27150440216064453},{"id":"76155785","wikidata":"https://www.wikidata.org/wiki/Q418","display_name":"Telecommunications","score":0.09495565295219421}],"counts_by_year":[{"year":2024,"works_count":19,"oa_works_count":19,"cited_by_count":2},{"year":2025,"works_count":1,"oa_works_count":1,"cited_by_count":4},{"year":2026,"works_count":0,"oa_works_count":0,"cited_by_count":8}],"display_name_alternatives":["Naoshi Kunimura"],"block_key":"n kunimura","works_api_url":"https://api.openalex.org/works?filter=author.id:A5069334608","awards_count":0,"awards_api_url":"https://api.openalex.org/awards?filter=investigators.author.id:A5069334608","updated_date":"2026-11-14T11:48:19","created_date":"2024-01-25T00:00:00"}